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Summary 
 
Early detection of breast cancer is an important public health policy. Programs of regular 
screening examinations have been widely established in an attempt to detect the disease 
when the primary tumour diameter is small. In South Australia, BreastScreen SA 
suggests that women between the ages of 50 and 70 years be screened every 24 months. 
Our aim in this paper is to make assessments of various screening procedures by using 
statistical models with parameters estimated exclusively from South Australian data. We 
establish a relationship between primary tumour diameter and ultimate survival time. We 
estimate an advantage of 2.9 (.7) years in median survival time for those women detected 
with the disease by BreastScreen SA, compared with an unscreened population. We 
construct a computer model from which we determine the consequences of using a 12 
month screening interval, and also the effect of beginning screening at the age of 40 
rather than the current conventional commencement age of 50 years.  
 
 
 
Key words: breast cancer; South Australia; early detection; breast cancer screening; 
median survival time; computer model.  
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1. Introduction 
Breast cancer remains a severe health risk.  In South Australia a woman has an estimated 
lifetime chance of 1 in 13 of developing the disease, and this chance is doubled or tripled 
if there have been cases of breast cancer in close relatives. 
 
The prognosis at first detection involves many factors, including the size of the primary 
tumour, the disease stage, the tumour histology, the age and general health of the woman.  
However, the main methods of detection involve the primary breast tumour, the size of 
which is now regarded as a prime single predictor of the future course of the disease. 
There is a large body of literature concerning this issue spread over an extended period of 
time; for example, Fisher, Slack & Bross (1969); Duncan & Kerr (1976); Zurrida et al 
(1999). Detection programs attempt to find primary tumours early, before they have 
spread to local lymph glands, and beyond.  Such programs carried out on a regular basis 
are referred to as “screening”, with an individual set of examinations being called a 
“screen”. 
 
The principles of early detection have changed very little over the years. The present 
mechanics of screening women is, apart from technological advances in radiography, 
essentially the same as that used in the first major randomised clinical trial testing the 
effectiveness of regularly screening female populations for breast cancer.  This trial was 
established in New York City in 1963, and it was known as the HIP (Hospital Insurance 
Plan) Study. Conclusions based on this trial, and others, have been summarised in a 
review paper by the US Department of Health and Human Services entitled “Screening 
for Breast Cancer” (USDHHS, (1996)).  It was in the analyses of the results of such 
studies that technically challenging problems were discovered. 
 
It is intuitive that screen detected disease is generally at an earlier stage than “naturally 
reported” disease.  The difference between the average age of breast cancer patients 
whose disease is self detected and the average age at which they would have had the 
tumour detected under a screening program is called the lead-time.  Lead-time for breast 
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cancer is of the order of six to eighteen months and it must be taken into account in 
survival analyses following any trial to avoid systematic biases. 
 
With regard to screening recommendations, these too have not altered greatly over recent 
years.  It is strongly advised to screen women between the ages of 50 years and 70 years 
every 24 months using mammography, clinical breast examination and breast self-
examination as a joint detection modality. It is unclear whether women outside this age 
range benefit significantly from screening every 24 months.  Nevertheless, women of any 
age who are thought to be at a higher risk of getting breast cancer due to its presence in 
close relatives are advised to enrol in an early detection program.  
 
It is reported in USDHHS (loc cit) that screening appears to lead to a reduction in breast 
cancer mortality of at least 22%. However, this criterion of assessing the impact of a 
screening program has recently been criticised; Black, Haggstrom & Welch (2002); 
Tabar et al (2002); Juffs & Tannock (2002).  We believe that a more useful and direct 
interpretation of the benefits of breast cancer screening for a woman who is considering 
entering a program is in terms of the extra lifetime that she may gain. Hence, all our 
results in this paper are expressed in terms of additional survival time past the age at 
reporting.  We note that survival times have also been used by Jansen & Zoetelief (1995). 
 
In 1989 BreastScreen SA was established to join a National Programme of Early 
Detection of Breast Cancer.  The South Australian affiliate services a total population of 
about 142,000 women aged between 50 years and 70 years. Annually between 60,000 
and 70,000 screens are carried out, providing a screening service with a screening interval 
of 24 months (Robinson et al (1996)). 
 
The main aim of this paper is to demonstrate the possibility of evaluating the impact of a 
screening service using only data from the service itself, and additional data from the 
local population-based cancer registry. Our population consists of the women in South 
Australia and the criterion of evaluation is in terms of additional life-time past the age at 
which breast cancer was first diagnosed.  No data external to South Australia has been 
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used in our evaluation, thus eliminating the concerns of bias due to population mismatch. 
We emphasise that the models developed in this paper are specifically designed for the 
data that has been routinely collected in South Australia. It is not anticipated that these 
models will necessarily be useful elsewhere. The results reported here are the culmination 
of efforts spanning some 30 years and we believe this to be an original way to assess the 
effect on survival of early detection of breast cancer. 
 
In brief, Section 2 is a glossary of acronyms, notation and definitions. In Section 3, we 
establish the method of estimating median additional survival time following the 
detection of a primary tumour which is the measure we use to assess the advantages of 
early detection. Section 4 demonstrates the survival advantages of early detection and 
quantifies the achievement of BreastScreen SA. Section 5 consists of a technical 
description of breast cancer screening, develops procedures for some necessary modelling 
and estimation processes, and extrapolates the results of Section 4. Section 6 summarises 
the findings of this paper and discusses potential biases in the estimation of survival time. 
 
2. Notation, definitions and data sets 
This section is designed to help readers by defining terms and important acronyms here 
for quick reference, and describing the various data sets used in this paper. 
 
1. a; the age in years at which a primary breast tumour is first detected. 
2. x; the diameter in centimetres of the tumour reported at a.  
3. m(a,x); the median additional survival time in years of a woman at a with x. A 
fitted Cox proportional hazards model, , specified in Section 3 is used 
to calculate values for m(a,x). The survival time of a woman past a is a 
random quantity with a mean that cannot be accurately estimated from our 
current data sets.   
ˆ ( , )m a x
4. ; the calculated gain in median survival for 
tumours detected at with 
1 1 2 1 2 2ˆ ( , ) ( ) ( , )G m a x a a m a x= − − − ˆ
1a 1x  and at  with 2a 2x , after correcting for lead-
time   2 1a a−
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5. ( ; )x t β ; the diameter of a primary tumour of age t defined by the standard 
biological model
0
( ; ) tx t x eββ = ; see Kusama et al (1972). Here, 0x is the 
diameter of a single cell, approximately .002cm, and β  is the tumour growth 
rate. 
6. SACR; South Australia Cancer Registry 
7. BSSA ; BreastScreen SA 
8. SACR diameter data set; consisting of 1346 cases of breast cancer 
accumulated by the SACR in the period 1980-86. For each case in this data 
set, the age of the woman reporting the disease, the diameter of the reported 
tumour and the survival time from reporting until death or surviving until 
December 2002, is available. The survival times of these cases have minimum 
and maximum periods of observation of 16 and 22 years. For this data set, 
58.8a =  and 3.2.x =  
9. SACR conditioned data set; consisting of a sub-set of 627 cases of the SACR 
diameter data set with 55 < a < 75 and  x ≤  5.5. The restrictions on the ranges 
of a and x make it possible to accurately determine median survival time for 
the specific values of a and x that are appropriate for screening designs 
presented later in this paper. For this data set, 64.5a = and 2.60x = . 
10. BSSA data set; consisting of the 2769 cases of breast cancer detected in 
women who entered the BreastScreen SA screening program between 50 and 
70 years of age during the period 1990-2002. For this data set, 60.9 a =  
and 1.65x = .  
11. SEER data set; consisting of cases extracted from the publicly accessible data 
base of the SEER program (2003) which consists of over 400,000 cases of 
breast cancer. A sub-group of 3057 SEER cases from 1989-90 was matched as 
closely as possible to the same a and x specifications of the SACR conditioned 
data, giving an approximate 5:1 ratio in the sample sizes of the two data sets. 
Prior to 1989 reporting diameters were not recorded for breast cancer cases in 
the SEER data base. The choice of the SEER data from 1989-90 was an 
attempt to make the survival characteristics of the two matched groups as 
comparable as possible, although there are possibly unknown effects of case-
 7
mix and temporal shifts between the two sets.  As the maximum possible 
survival time for the SEER data is approximately 12 years, the estimation of 
median survival time conditioned on a and x is currently restricted for the 
SEER data. For this data set, 64.6 a =  and 2.55.x =   
12. SACR incidence data set; consisting of the year of reporting and a for 8582 
cases of breast cancer registered by the SACR for the period 1977-92. 
(Epidemiology of Cancer in South Australia (1993)). The time period 1977-92 
essentially precedes the introduction of formal breast cancer screening in 
South Australia after which the concept of random self-reporting no longer 
can be assumed. The frequency distribution of a, accumulated over 1977-92, 
is shown in Table 3 in Section 5.2. For this data set, 60.5.a =  
 
3. Estimation of median survival time 
In this section we consider the estimation of median survival time in some detail, since 
this is the measure by which we assess the performance of screening designs of the type 
currently practiced in South Australia. It is also the measure that we use to quantify the 
advantages of alternate screening designs.  
 
Breast cancer survival data is available for two distinct but generally comparable 
populations. The primary data used for survival analysis is the SACR conditioned data 
(see 2.9). A Cox proportional hazards model was fitted to these survival data, and linear, 
quadratic and interaction terms for a and x were investigated. Full diagnostic checks for 
proportionality led to a model with linear and interaction terms for a and x. Influence 
plots confirmed that there were no data points with undue influence. Scaled Schoenfeld 
residual plots for the interaction model show no departures from proportionality.   
 
The adequacy of calculating median survival time from this specific 
parameterization of the Cox model fitted to the SACR conditioned data is illustrated in 
Table 1.  The investigations detailed in the previous paragraph do not specifically address 
the estimation of median survival. For various diameter groupings, median survival time 
is calculated directly by the non-parametric actuarial lifetable method and each value is 
ˆ ( , )m a x
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closely reproduced by ˆ ( , )m a x  determined from the Cox model. The technical reasons 
for the particular choice of diameter groupings in Table 1 have been previously discussed 
in Tallis et al (2003).  
 
 Table 1: Comparison of actuarial and Cox model median survival times 
x N a x Actuarial 
median
(se)
ˆ ( , )m a x  
(se) 
 
z-score
   
≤ 1.2 67 64.2 0.94 18.71 
(1.08)
18.97 
(1.82) 
-.12
1.3-1.7 107 64.9 1.50 16.84 
(1.45)
16.50 
(1.11) 
.19
1.8-2.2 118 64.7 2.00 13.60
(1.13)
14.74 
(0.96) 
-.77
2.3-2.7 102 64.2 2.50 11.67 
(0.95)
13.24 
(0.81) 
-1.26
2.8-5.5 233 64.6 3.93 9.04 
(0.57)
9.41 
(0.60) 
-.45
 
 
The agreement between each pair of median survival times, actuarial and ˆ ( , )m a x , is 
assessed by a z-score. It can be seen in Table 1 that only one z-score is greater than 1 in 
absolute value. By squaring and summing these z-scores, we get an approximate and 
perhaps conservative 22χ =2.42, with P = .30. Thus we believe that calculated from 
the fitted Cox model adequately represents median survival time in the SACR 
conditioned data over these ranges of a and x. 
ˆ ( , )m a x
 
The survival distributions of the SACR conditioned data and the SEER data (see 2.11) 
were examined by using actuarial survival curves, and the results of these comparisons 
are shown in Table 2, conditioned on the diameter groupings used in Table 1. In order to 
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make the survival times from the two data sets comparable, the survival times in the 
SACR conditioned data were re-coded so that deaths recorded after 12 years became 
censorings at 12 years. The result of accumulating the probabilities from the five 
diameter groups by using the Fisher method is  with P=.62; Cox & Hinkley, 
(1974). Two summary statistics, the 75th percentile and the survival after 11 years S(11), 
are also shown in Table 2 to illustrate the magnitude of the differences in survival 
between the two groups. The conclusion is that overall survival, and survival conditioned 
on diameter, is not materially nor demonstrably different in the two data sets matched on 
a and x, but not on other factors which may influence survival. It was reassuring that the 
Australian and American breast cancer survival experiences showed a close agreement, 
which was anticipated a priori, since a substantial divergence would have lead to an 
uncomfortable inferential impasse. 
2
10 8.07χ =
 
We have compared the survival distributions determined from the SACR conditioned 
data against the SEER data because of the critical role that estimated median survival 
time plays in our assessments of screening designs. Nevertheless, it must be noted that, 
since the survival distributions can only be compared over 12 years, the power of 
discrimination may be weak and for reasons previously stated, the two groups cannot be 
regarded as absolutely exchangeable. (see 2.11) 
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Table 2: Comparison of South Australian & SEER Actuarial Survival Curves 
        x Mantel-Cox   
P-value 
75th Percentile S(11) 
  SA SEER z-score SA SEER z-score 
        
≤5.5 .267 5.58 
(0.38) 
5.39 
(0.19) 
.45 .533 
(.055) 
.569 
(.071) 
-.40 
        
≤1.2 .904 10.55 
(0.75) 
10.82 
(0.60) 
-.28 .716 
(.023) 
.743 
(.077) 
-.34 
1.3-1.7 .139 7.55 
(0.91) 
9.25 
(0.61) 
-1.55 .626 
(.046) 
.696 
(.031) 
-1.26 
1.8-2.2 .248 5.07 
(0.77) 
6.35 
(0.57) 
-1.34 .551 
(.031) 
.612 
(.051) 
-1.02 
2.3-2.7 .730 5.38 
(1.03) 
5.20 
(0.41) 
.16 .539 
(.115) 
.551 
(.076) 
-.09 
2.8-5.5 .779 4.02 
(0.49) 
3.47 
(0.20) 
1.04 .425 
(.073) 
.439 
(.109) 
-.11 
 
 
4. Survival advantage of early detection of breast cancer  
4.1 An illustration 
In order to illustrate the effect of early detection on survival, consider the example of a 
woman with a tumour which remains undetected until it reaches x=3 by a=65, 
with . This combination of a, x and is used as a benchmark in this 
section, with a and x being a reasonable approximation to the historical average reporting 
age and diameter of the SACR diameter data (see 2.8).   
ˆ (65,3)=10.9m ˆ ( , )m a x
 
Suppose that the tumour was discovered at a less than 65 when x=1.  For the present 
purposes we take β =.07, determined later in Section 5.  Applying the model for tumour 
growth x(t;β ) (see 2.5) it is easily found that x=1 when a = 63.7, and consequently 
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ˆ (63.7,1) = 19.2m .  With a1 = 63.7, x1 = 1 and a2 = 65, x2 = 3, then G = 7.1 (see 2. 4). 
Similarly, if the tumour was detected at x = 2, or x = 4 or x = 5, the same argument gives 
values of G as 3.5 – 2.0 and -3.8, all with respect to the benchmark These 
figures clearly suggest the possible advantages of early detection of the disease. 
ˆ (65,3).m
 
4.2 Results using Breastscreen SA data 
Now we apply the concepts introduced in Section 4.1 to assess the impact of the breast 
screening program of BreastScreen SA during 1990-2002.  The first task is to establish 
the appropriate benchmark for this period. 
 
From the SACR diameter data, naturally reported cases of breast cancer in South 
Australia have the historical average tumour diameter of 3.20cm. However, work 
reported in Tallis, Leppard & O’Neill (2003) suggests that this naturally reported 
diameter may have been reduced over recent years to 2.44cm. The SACR has 
independently published in an annual report results in a tabular form for 1997-99, from 
which we estimate 60.5a = and 2.41x =  for an unscreened group of women. These last 
two estimates are in substantial agreement, and we use our estimate of x=2.44 to define 
the benchmark in subsequent analyses. The precise reasons for the reduction over time in 
average reporting diameter in an unscreened group are not known. This same 
phenomenon has been observed in the United States where x  varied from 3 to 2.1 over 
the period 1970 to 2000; Fisher et al (loc cit), Cady (1997).  
 
A woman having the average detection age and tumour diameter of the BSSA data (see 
2.10) has (60.9,1.65)=19.79 (1.11), where the estimated standard error in parentheses 
has been calculated by using bootstrap techniques with 1000 repeated samplings; Efron & 
Tibshirani (1993). In the absence of screening, a tumour with x=1.65 would grow to 
x=2.44 in .5 years, using the arguments of the previous section, and hence defines a 
benchmark of x=2.44 at a=61.4 with (61.4,2.44)=16.36 (0.83). Thus for this situation 
G=2.93 (0.68).  
mˆ
mˆ
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Since, as discussed above, it appears that the average tumour diameter of an unscreened 
populations is decreasing, we have also used for comparison the benchmark tumour 
diameter of 2.1 cm reported by Cady (loc cit), giving a survival gain of G=1.70 (0.47). 
These assessments of the advantages of screening in terms of increased gain in survival 
time emphasise the key role played in such assessments by the choice of a, x and  that 
define the benchmark.  
mˆ
 
5. Statistical modelling of breast cancer screening for South Australia 
In Section 4.2 we have used G as an assessment of screening as performed by 
BreastScreen SA. We conclude that their screening program with a 24 month period 
between examinations leads to a gain in survival of approximately 3 years for the average 
woman detected under the screening program. This is an encouraging and important 
result.  In the following sections we develop a structural framework and statistical 
estimates required to investigate the effect on G of reducing the screening interval from 
24 to 12 months, and of beginning screening at 40 rather than 50 years of age. 
 
5.1 Definitions of components for the screening process 
It is straightforward to heuristically review the broadest aspects of screening.  For 
example, suppose a woman enters a screening program at the age of 50 years.  She has 
been continuously subjected to the risk of initiating a breast tumour during the previous 
30 years or so.  There are three possible outcomes for a woman entering the screening 
program with an undetected tumour. She could have the tumour detected by screening, 
she could self-detect the tumour between screens, or she could die before the tumour is 
detected in either way. These events are assumed to be dictated largely by the rate of 
initiating tumours, tumour size and rate of growth, the sensitivity of the screening 
procedure for detecting tumours, and the likelihood of the woman finding and reporting 
the disease herself in the presence of the competing risk of natural mortality.  If a tumour 
of a particular size is found, then the patient’s survival prospects will depend on, at the 
very least, the age of the woman and the size of the tumour. 
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In this way we identify six basic components which must be known in order to develop a 
basic understanding and quantification of screening.  These components are 
(1) The probability of surviving to a for South Australian women, S(a); 
(2) The probability of self-detecting a primary tumour less than x, P(x); 
(3) The probability of detecting a primary tumour of diameter x when subjected to 
screening, r(x); 
(4) The distribution of growth rates, β , of primary tumours, ; ( )b β
(5) The probability of a woman ever contracting breast cancer, ; in the absence of 
natural mortality, and given that the woman contracts the disease, the probability 
of initiating the disease by age y, H(y). 
γ
(6) The median survival time of a women at a with x, m(a,x).  
 
The function S(a) is obtained from population life tables published by the Australian 
Bureau of Statistics. The function m(a,x) has been estimated in Section 3.  The functions 
P(x) and r(x) were estimated in Tallis et al (loc cit), and here we use the notation  and 
 respectively for these functions with parameters set at the maximum likelihood values 
given in that paper. The functions
Pˆ
rˆ
( )b β  and H(y), and , are estimated in the following 
section. 
γ
 
 
5.2 A model for breast cancer incidence 
The SACR incidence data (see 2.12) is shown in Table 3 with the frequency distribution 
denoted as aI . To derive a tailored and credible model to simulate the distribution of aI is 
a detailed and subtle process. However, here we restrict the derivation to a discussion of 
the mean of aI  and a brief outline of distributional properties. 
 
Given a woman does contract the disease, let A be the age at which the woman first 
detects a primary breast tumour, the age at reporting for short. Clearly, A is a random 
variable, and we let Pr (A=a) = f(a), 10020∑ f(a) = 1. Under the same conditioning, the 
probability that a woman reports at A=a, in the presence of natural mortality, is  
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f(a) S(a), from 5.1(1). Thus, the unconditional probability that a woman reports at A=a is 
γ f(a)S(a), from 5.1(5). 
 
Now define as the total number of women born a years before either 1977, or 1978, 
…, or 1992. Then 
aN
a aE Iλ = = aN γ f(a)S(a) is the expected total number of women who 
report at A=a during the 16 years 1977-1992.  We now briefly show that for all a, the 
aI are Poisson distributed with parameter aλ , and that the aI are all mutually independent.   
 
Referring to Table 3, consider 40I . The 16 years of data collection is 1977-92, and 40I  is 
built up from reported cases from each of these years, since results have been pooled.  
Now, only women born in 1937 can contribute to the 40 year old incidence figure for 
1977.  Women born in 1938 contribute to the 40 year incidence for 1978, and so on, to 
women born in 1952 who contribute to the incidence figure for 1992.  The 16 
contributions are obviously independent, and since γ f(a)S(a) is small, the random parts 
adding to 40I  are Poisson distributed, and consequently so is 40I .   
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Table 3: Age-specific breast cancer incidence 1977 - 1992 
 
Age(a) aI  aλ  a a
a
a
-d I λλ=
Age(a) aI aλ  a a
a
a
-d I λλ=
≤30    92     91.1     0.091 61 215  199.6     1.093
31   26    36.0   -1.672 62 187  200.1    -0.925
32   45    43.2    0.275 63 230  203.7     1.845
33   49    50.5   -0.209 64 206  204.7     0.093
34   64    60.8    0.416 65 194  211.5    -1.202
35  74    67.2    0.836 66 221  204.9     1.125
36   85    76.2    1.004 67 213  197.0     1.141
37   71    85.5   -1.567 68 214  199.6     1.021
38   97    95.9    0.111 69 201  195.4     0.398
39  106   110.1     -0.386 70 191  198.1    -0.504
40  120   115.5  0.420 71 181  188.4    -0.542
41  133   120.8      1.114 72 185  182.0     0.223
42  130   135.2     -0.446 73 164  175.5    -0.869
43  140   139.0      0.084 74 159  167.0    -0.622
44  131   149.2     -1.487 75 139  163.9    -1.946
45  161   152.4      0.697 76 158  156.8     0.100
46  154   154.9     -0.072 77 139  143.3    -0.357
47  161   160.3      0.058 78 132  134.5    -0.218
48  178   159.8      1.442 79 109  126.4    -1.551
49  162   167.0     -0.386 80 114  119.6    -0.512
50  194   177.6      1.234 81 94  107.2  -1.274
51  156   167.4     -0.880 82 109   96.1    1.312
52  173   179.6     -0.492 83 106   86.2    2.130
53  187   182.5      0.336 84 79   78.9  0.010
54  161   184.1     -1.703 85 75   70.2  0.569
55  188   193.6     -0.402 86 66   63.0  0.383
56  170   191.3     -1.543 87 58   50.2  1.099
57  196   191.5      0.328 88 52   42.1  1.522
58  206   198.6      0.524 89 27   37.0  -1.650
59  203   197.8      0.371 ≥90 128  121.1     0.624
60  211   211.7     -0.045    
   90 2
a
a=30
D d= =∑ 56.6
   2
55Pr ( D 56.6) .42χ= ≥ =
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Of course, the women born in 1937 contribute to 41I  in 1978, 42I  in 1979, and so on.  
These contributions are generated from a multinomial with 61 probabilities, γf(a)S(a), 
and, since the number of women in the 1937 cohort is large, the random variables 
generated by the multinomial, in the limit, are distributed as independent Poisson 
variables.  The same is true for all cohorts who contribute to the 1977-92 incidence years.  
Finally, ( )
aa
I Poisson λ∼  and , ,a bI I a b≠ , are independent for all a and b. A detailed 
mathematical demonstration of these results can be achieved using probability generating 
function techniques outlined in Chapter 12, Volume 1 of Feller (1960). 
 
We have chosen the standard biological model for tumour diameters, ( ; )x t β (see 2.5).  
Now we choose a density function ( )b β  for the growth rateβ , of the form 1( )b β θ= and 
2( ) 1b β θ= − . This form allows just two values ofβ  mixed by θ  and 1 θ− , reflecting  
the current medical thinking of “slow” and “fast” growing tumours. The most recent 
discussion of tumour growth rates in a human population are reported in Kusama et al 
(loc cit) and Vorherr (1981). 
 
Given a woman does contract the disease at some time during her life, there are two 
additional variables to model: Y, the age at initiation of the disease; T, the time delay to 
reporting the breast tumour. The discrete probability density function (pdf) of T 
is ( ; ) ( ( ; )) ( ( 1; ))p t P x t P x tβ β= − − β , for integer values of t, since ( ; )x t β  is a strictly 
monotone increasing function of the delay to reporting.  The function P is the cumulative 
distribution function (cdf) of self-reported diameters, x; see Tallis et al loc cit.  Since the 
model ( )b β  has two values of ,  and , this gives . 
Similarly, we let the discrete pdf of Y be 
β 1β 2β 1 2( ) ( ; ) (1 ) ( ; )p t p t p tθ β θ β= + −
( ) ( ) ( 1)h y H y H y= − − , where the function H is 
the cdf of the age at initiation of a breast cancer tumour. Since A is the age at reporting, A 
= Y + T, where Y and T are assumed independent. Since Pr (A = a) = f(a), then f h p= ∗ ,  
( )
a
y
i.e. ( ) 
20
( )f a h a y
=
= −∑ , with h(y)=0 foy p r y < 20 by assumption. 
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To complete the definition of , we need to specifyaλ ( )f a in greater detail. We use 
 and 21( ) 1 exp( ( ; ) )P t x t
αα β= − −
* *
* *
( ) (20)( )
(100) (20)
H y HH y
H H
−= −  
where * 1 2( ) log(1 exp( ))H y yδ δ= + + . The choice of the form of P was suggested by 
years of past experience, and an empirical analysis of the SACR diameter data. The form 
of was suggested by a graphical display of the distribution of *( )H y aI in Table 3, taking 
into account the form of P(t). This analysis suggested that the pdf of H(y) had a sigmoid 
shape and this particular property of the data is necessarily reflected in our parameterised 
version of H (y).  Truncation at ages 20 and 100 keeps estimates within realistic bounds.  
 
The set of parameters are estimated by standard maximum 
likelihood techniques. The log-likelihood function,
1 2 1 2 1 2( , , , , , , , )π γ δ δ α α θ β β=
log L , is expressed as two components 
1 2log log logL L= + L
( )290 1345 1 2 2 1
30 1
( log ( ) ( )) log log ( 1) log aa a a j j
a j
I x xλ π λ π α α α α
= =
= − + + + −∑ ∑ −  
In the expression for , requires values for , the size of the population 
at age a accumulated over the period 1977 to 1992. This data is obtained from population 
figures published by the Australian Bureau of Statistics. The expression is obtained 
by differentiating P with respect to x, and evaluated using the SACR diameter data. The 
likelihood parameter estimates and standard errors are given in Table 4. The estimates  
and  conform to the results reported by Kusama et al (loc cit).  
1log L ( )aλ π ( )aN S a
2log L
1ˆβ
2βˆ
 
It should be noted that the breast cancer cases defining  are a subset of the cases 
defining . Since a and x are essentially independently distributed (see Tallis et al 
(loc cit)) the likelihood procedure specified above is appropriate. The issue of 
independence is further demonstrated by a correlation of .031 (.027) between a and x in 
the SACR diameter data, where there is also no evidence of higher order regression of x 
on a. 
2log L
1log L
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Let be the maximum likelihood estimator forπ . The theory of section 4(b) of Tallis & 
Chesson (1976) was modified to deal with parameter estimates which are generated 
externally to the main data set, whose agreement with the model is to be tested. From this 
work, it can be shown that conservatively, 
πˆ
90 90
2 2 2
55
30 30
ˆ ˆ( ( )) / ( )a a a a
a a
D d I λ π λ π χ
= =
= = −∑ ∑ ∼ 255Pr ( D 56.6) .42.χ= ≥ = and  
Analysis of the standardised residuals produced a mean and standard deviation of .01 
and .97. There is no regression of on a; all terms of a polynomial regression of order 3 
are non-significant with p-values greater than .3 and . There is no suggestion 
of non-normality in the distribution of  as assessed by both the Anderson-Darling and 
Shapiro-Wilk tests of normality. Hence, overall, there is no evidence that our model does 
not fit the SACR incidence data. 
ad
ad
2 2.2%R =
ad
 
Table 4: Parameter estimates (se) of cancer incidence model  
Parameter Estimate seγ 0.187 0.008  
1δ -6.890 0.555 
2δ 0.202 0.017  
1α 0.121 0.007 
2α 1.636 0.032 
θ 0.354 0.023  
1β 0.018 0.002  
2β 0.101 0.014
 
 
5.3 A computer model for screening in South Australia 
The six breast cancer screening components detailed in Section 5.1, which have been 
estimated using South Australian data, have been incorporated into a computer model of 
the screening process specifically for South Australia. We examine the consequences of 
both reducing the screening interval from 24 months to 12 months, and beginning 
screening at 40 rather than 50.  There is an extensive literature of mathematical modelling 
and computer simulation of breast cancer screening processes,  some of the earliest being  
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Knox (1973),  Schwartz (1978) and  the evolving general cancer screening simulation 
project MISCAN (1984). More recently Jansen & Zoetelief (loc cit) have produced a 
simulation program which calculates the benefit of breast cancer screening based on the 
reduction in tumour size at detection and survival as a function of tumour diameter. The 
technical features of breast cancer screening have been extensively reviewed in O’Neill, 
Tallis & Leppard (1995) where further references are given. 
 
The logical structure of the model is briefly outlined, using the notation of the six 
components discussed in Section 5.1. A cohort of (computer generated) women is 
progressively aged from birth with the cohort continuously subjected to natural mortality 
specified by S(a). Tumours are initiated at each age y according to  and , with a 
growth rate assigned to these tumours according to
γˆ ˆ ( )H y
( )bˆ β . Thereafter these tumours 
increase in diameter over time following initiation t, according to 0
tx eβ , for 
β either 1ˆβ or 2βˆ . Women who initiate a tumour may self-report at a=y+t as specified 
by , (see Section 5.1) subject to surviving to a specified by S(a). A screening 
procedure defined by  (see Section 5.1) is introduced for those women who are alive 
at a designated age and who have not previously self-reported a tumour before this 
age. An initial screening examination is made at , with further screening examinations 
made at intervals of l months until the women reach age . The general screening design 
is designated as D( , l, ). Within the period  to  each woman will either   
( )(Pˆ x t )
ˆ( )r x
Sa
Sa
Fa
Sa Fa Sa Fa
a) self-report a tumour at a known  a and with a known x 
b) have a tumour detected at a known  a and with a known x by a screening examination  
c) die through natural mortality before either (a) or (b) occurs  
d) survive to without either (a) or (b) occurring.  Fa
The group of women who have a tumour detected at any periodic examination or who 
self-report a tumour at any time between two successive examinations are considered 
detected under the screening design. The average detection age, 1a , and the average 
reporting diameter, 1x , are determined from this group to represent a screened population, 
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with median survival time 1 1( , )m a x .  The appropriate comparison is made using the 
group of women with tumours detected using screening design D( , *, ), representing 
only self-reported tumours over the period  to and without the imposition of any 
screening examinations.  The average reporting age,
Sa Fa
Sa Fa
0a , and the average reporting 
diameter, 0x , are determined from this group to represent an unscreened population, with 
median survival time 0 0( , )m a x .  The gain of the screening design is assessed by 
1 1 0 1 0 0( , ) ( ) ( , )G m a x a a m a x= − − − . 
 
An initial basic assessment of the performance of the model was made by specifying a 
design that accumulates self-reported cases over all ages without involving screening. 
The results for this design, labelled Model-unscreened, are shown in Table 5. Equivalent 
observed values from a SACR 1997-99 report are also shown in Table 5. We tested the 
model further. For the BSSA data, 57.7Sa = and 65.3Fa = . These values arise because 
the data from BreastScreenSA are produced by a complex mixture of screening designs. 
Each woman examined has an age between 50 and 70 years at which she began her 
screening program, and a time under observation between one and twelve years, 
depending on the calendar year between 1990 and 2002 at which she began her particular 
screening program. These features of the data specify a value of  and  for each 
woman, from which 
Sa Fa
Sa and Fa were calculated. The results for the model with these 
settings are shown in Table 5 labelled Model-24. Because of the close agreement between 
the results from the observed data and the model, we confidently use the model in  
Section 5.4 to investigate various screening designs.   
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Table 5: Verification of computer screening model 
 Design a  x  ˆ ( , )m a x Difference in median 
survival  
(lead-time corrected)
SACR 1997-99  60.5 2.41 17.26  
Model-Unscreened D(0,*,100) 60.8 2.49 16.87 .09 (.13) 
      
BSSA data   60.9 1.65 19.79  
Model-24  D(57.7,24,65.3) 61.1 1.53 20.24 .35 (.24) 
 
5.4 Applications of the computer screening model 
We firstly consider what might have been achieved had BreastScreen SA used a 12 
month screening interval rather than a 24 month interval. This is calculated using the 
design labelled Model-12. The results are compared to those for Model-24 with the 
values of G shown in Table 6. We estimate that there may have been a marginal 
advantage in using a 12 month screening interval. 
 
Table 6: Estimated G for BreastScreen SA using 12 month screening interval 
 Design a  x  ˆ ( , )m a x G 
      
Model-24 D(57.7,24,65.3) 61.1 1.53 20.24  
Model-12 D(57.7,12,65.3) 61.0 1.19 21.51 1.25 (.58) 
 
The results presented in Table 6 are based on the current average screening exposure time 
of approximately 7 years. We now use the model to estimate the advantages of long term 
screening. In Table 7, results are shown using the model with the self-reporting 
function . The model is specified for an unscreened population over the age of 50, and 
for screening designs beginning at age 50, with 24 and 12 month screening intervals. The 
model with a 24 month screening interval is compared to the model for an unscreened 
population, and the model with a 12 month screening interval is compared to the model 
Pˆ
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with a 24 month screening interval. For illustration, the parameters defining  have been 
modified to produce a variation in self-reporting, , which has an average value of 2. 
This change approximates the self-reported diameter of Cady (loc cit), substantially 
lowers the benchmark and thereby reduces the possible effect of screening, as previously 
discussed in Section 4.2. Corresponding results are produced for as for . 
Pˆ
*P
*P Pˆ
 
Table 7: Comparison of screening designs beginning at age 50 
 
 Screening interval  Design a  x  ˆ ( , )m a x  G 
       
 Unscreened D(50,*,100) 67.30 2.49 10.37 (0.81)  
Pˆ  24 month D(50,24,100) 66.79 1.52 14.49 (1.16) 3.6 (0.82) 
 12 month D(50,12,100) 66.52 1.09 16.30 (1.44) 1.5 (0.64) 
       
 Unscreened D(50,*,100) 67.26 2.00 12.12 (0.99)  
*P  24 month D(50,24,100) 66.82 1.36 14.90 (1.03) 2.4 (0.59) 
 12 month D(50,12,100) 66.58 1.04 16.29 (1.24) 1.1 (0.49) 
 
 
There are a number of issues that arise from Table 7.  
• The value of G=3.6 achieved for  and a 24 month screening interval agrees 
reasonably well with G=2.9 (.68) calculated for BreastScreen SA in Section 4.2. 
The value of 
Pˆ
a  from BSSA data is about 6 years less than a  of the model. This 
occurs because BreastScreen SA currently has a period of observation of twelve 
years whereas the design setting summarises a cohort screened every 24 months 
after fifty. 
• The results using  suggest that there is an additional survival advantage of 1.5 
years for a screening program with a 12 month screening interval when compared 
to a program with a 24 month interval. This agrees with the value of 1.25 shown 
for Model-12 in Table 6.  
Pˆ
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• The results using  parallel those found for , but to a lesser amount, again 
emphasising the role that the benchmark plays in these assessments. 
*P Pˆ
 
We use our model to generate results equivalent to those shown in Table 7, but using 40 
rather than 50 as the age of initial screening. The corresponding values of G are  
3.41 (0.78) and 1.69 (0.68), which are essentially the same as those shown in Table 7.  
 
A prominent question in the breast cancer screening literature concerns the efficacy of 
beginning screening at the age of 40 rather than 50, the currently accepted age at which 
screening programs start ; USDHHS (loc cit). In order to examine this question, it is 
necessary to compare the results from a group of women who begin screening regularly 
from the age of 40, with the results from a group reaching the same age of 40 but who 
defer screening until age 50. This comparison produces a value G=.62 (.23) in favour of 
the group who begin screening at 40, for a screening interval of 24 months. A value of 
G=1.05(.49) is found for the group starting at 40, for a 12 month screening interval. 
 
 
6. Discussion and Summary 
We believe that we have achieved the main aims of this project as outlined in the 
Introduction. A random sample of women who reported with breast cancer during the 
period 1980-86 defined the SACR diameter data. This set specified the reporting age a, 
the diameter of the primary tumour x, and the survival time and status of the patient at the 
end of 2002. With this information we were able to restrict a and x to form the SACR 
conditioned data which was used to develop a Cox proportional hazard model with 
covariates a and x from which we estimated the median additional survival time after 
reporting, . Using this quantity, we provided in Section 4.1 some simple 
illustrations of the effect on survival of early detection of the disease, and introduced the 
concept of benchmark from which early and late detection can be measured and assessed 
in terms of additional survival time. Screening data from BreastScreen SA was evaluated 
in Section 4.2. It was found that the reduction in primary tumour diameter at detection 
due to the screening program produces an estimated gain in median survival time of 
( , )m a x
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about three years. This estimate is encouraging, but perhaps a more conservative way of 
interpreting it is to use the standard error to conclude that the gain should be at least 1.5 
years. Further, to put these results into perspective, the benchmark median survival 
represents a loss of 6 years when compared to normal median survival. It appears that 
under screening, about 3 of these years are recovered. 
 
The interval between screens in the BreastScreen SA program is 24 months and the target 
group of women are between 50 and 70 years of age.  What may have been the outcome 
had BSSA used different specifications?  In order to address this question, we developed 
a computer program in Section 5 which closely approximates the BSSA screening 
experience. The modelling to develop this computer program involved six basic 
components and each component required estimation.  We restricted ourselves entirely to 
data held by the SACR and BSSA for this task. Part of the estimation problem is dealt 
with in this paper, and the rest is published in Tallis et al (loc cit). The computer model, 
using well defined estimates of its parameters, was run first with the current BSSA 
screening interval of 24 months for women in the age range of 50 to 70. The computer 
results, in terms of the average age and primary tumour diameter, were very close to the 
observed BSSA figures. Since the computer program appeared to faithfully reproduce 
reality, we examined the outcomes for other settings. 
 
Using the computer program, for screening over 50, we estimate a survival advantage of 
1.5 years in favour of a screening interval of 12 months compared to an interval of 24 
months. For a screening interval of 24 months, a small advantage of approximately half a 
year was found for screening starting at 40 compared to the standard age of 50. For a 
screening interval of 12 months, an advantage of one year was found for screening 
starting at 40 rather than at 50.    
 
We have identified two potential sources of bias which could influence estimates of 
median survival time. The first is a registry problem. Inevitably some cases are lost to 
follow-up, thereby leading to over-estimates of median survival time, Tallis et al (1988). 
Fortunately, this is not a major issue in a professionally run registry such as the SACR 
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but, in any case, since we use the difference between two median estimates, any small 
biases would tend to negate each other. 
 
The second source of bias is less obvious and more technical.  An unscreened population 
such as that leading to the SACR conditioned data is in a steady state. In terms of x, the 
population is a mixture of two different growth rates, 1β  and 2β , but, conditionally on 
β , the cdf of x is invariant, see Tallis et al (loc cit). Screening changes this steady state 
by detecting the disease at considerably smaller diameters.  It can be shown that when a 
screened population is referred to a steady state, unscreened population for an estimate of 
survival time based on a and x, an over-estimate of perhaps half a year can be anticipated. 
 
We have examined both types of bias in detail and conclude that together, they should 
amount to less than .5 years.  In view of the size of the standard errors, and keeping in 
mind that the historical data of 1980-86 may underestimate the survival experiences of 
1990-2002, no attempt at any correction has been made. 
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